A Randomized Phase III Trial Comparing Trabectedin (Yondelis) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TSAR
- Sponsors Gustave Roussy cancer campus
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2018 According to a PharmaMar media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO).
- 11 Oct 2016 Primary endpoint (Progression Free Survival) has been met,according to the results published at the 41st European Society for Medical Oncology Congress.